Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab in refractory and/or non-criteria antiphospholipid syndrome: open-label phase II pilot
2020-004568-25Phase 2Terminated
- Sponsor
- Department of Clinical and Biological Sciences, University of Turin
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of belimumab in antiphospholipid syndrome (APS), sponsored by Department of Clinical and Biological Sciences, University of Turin. Primary endpoint: Number of Participants Experiencing Adverse Events. Started Aug 2021; status: terminated.
02
Drugs
belimumab
03
Conditions
antiphospholipid syndrome (APS)
Beyond the preview
Go deeper on 2020-004568-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004568-25.